Clinical Study ResultsTEV-44749 demonstrated significant improvement in social functioning and quality of life across multiple validated measures from baseline to week 8.
Financial ProspectsMedincell may receive up to $117M in development and commercial milestones for mdc-TJK, in addition to royalties on all net sales.
Safety ProfileTEV-44749 appears to have a meaningfully superior safety profile to existing long-acting injectable formulations of olanzapine, with no PDSS risk seen to date.